MedTrace Logo

Efficacy and Safety of Lucentis for Clinically Significant Macular Edema Secondary to Central Retinal Vein Occlusion

NCT01123564 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2010-05-14

No results posted yet for this study

Summary

This study aims to assess if Lucentis injection applied into the eye is superior to conventional treatment concerning the prevention of visual loss in patients having clinically significant macular edema secondary to retinal vein occlusion

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

ranibizumab

applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits

RADIATION

Argon laser treatment

Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.

Sponsors & Collaborators

  • University of Debrecen

    collaborator OTHER

  • University of Pecs

    lead OTHER

Principal Investigators

  • Zsolt Balla, MD PhD · University of Pecs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01123564 on ClinicalTrials.gov